These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

805 related articles for article (PubMed ID: 24027077)

  • 1. New drug targets in metastatic melanoma.
    Homet B; Ribas A
    J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for advanced melanoma: fulfilling the promise.
    Gogas H; Polyzos A; Kirkwood J
    Cancer Treat Rev; 2013 Dec; 39(8):879-85. PubMed ID: 23725878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
    Johnson DB; Sosman JA
    JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
    Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
    Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.
    Vella LJ; Andrews MC; Behren A; Cebon J; Woods K
    Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting metastatic melanoma.
    Flaherty KT
    Annu Rev Med; 2012; 63():171-83. PubMed ID: 22034865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for non-immunological molecular therapeutics in melanoma.
    Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
    J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating metastatic melanoma in 2014: what just happened and what is next?
    Chapman PB
    Am Soc Clin Oncol Educ Book; 2014; ():16-9. PubMed ID: 24857055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting oncogenic drivers and the immune system in melanoma.
    McArthur GA; Ribas A
    J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
    Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
    Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research progress in advanced melanoma.
    Luo C; Shen J
    Cancer Lett; 2017 Jul; 397():120-126. PubMed ID: 28385603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for metastatic malignant melanoma: old drugs and new strategies.
    Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
    Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
    Xu DH; Zhu Z; Xiao H; Wakefield MR; Bai Q; Nicholl MB; Ding VA; Fang Y
    Cancer Lett; 2017 May; 394():43-51. PubMed ID: 28254411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging targeted therapies for melanoma.
    Johnson DB; Pollack MH; Sosman JA
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
    Chen G; Davies MA
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic therapies for melanoma brain metastases: which drug for whom and when?
    Ramanujam S; Schadendorf D; Long GV
    Chin Clin Oncol; 2015 Jun; 4(2):25. PubMed ID: 26112811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy in melanoma.
    Kudchadkar RR; Smalley KS; Glass LF; Trimble JS; Sondak VK
    Clin Dermatol; 2013; 31(2):200-8. PubMed ID: 23438383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marker utility for combination therapy.
    Simeone E; Grimaldi AM; Ascierto PA
    Methods Mol Biol; 2014; 1102():97-115. PubMed ID: 24258976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new standard of care for metastatic melanoma?
    Sharma SP
    Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 41.